Event

Manuel Quaresma

PharmD
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial and Rare ;Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial

Amy L. Olson

MD, MSPH
National Jewish Health

Michael Kreuter

MD, PhD
Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklin;Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg,

Elisabeth Bendstrup

MD, PhD
Aarhaus University;Aarhus University Hospital

Christopher D. Wells

PhD
Decision Resources Group

Marlies Wijsenbeek

MD, PhD
Erasmus MC, University Medical Centre;Erasmus Medical Center;Erasmus University Medical Center

Baher Mounir

B Pharm
Boehringer Ingelheim Pharma GmbH & Co. KG

Leila Zouad-Lejour

MSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Aryeh Fischer

M.D.
Univ of Colorado Denver;University of Colorado School of Medicine

Current Treatment of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease